Vigilant Biosciences Announces OncAlert® Oral Cancer Product Line Now Shipping
December 20, 2016
FORT LAUDERDALE, Fla. – December 20, 2016 – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that its OncAlert® Oral Cancer product line is now shipping and available in select countries. Additionally, the Company announced the launch of its OncAlert Oral Cancer website, www.oncalert.com, an online resource for healthcare professionals interested in learning more about the OncAlert Oral Cancer product line.
Vigilant Biosciences’ OncAlert Oral Cancer product line includes the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test. The tests are based on the first and only commercially available technology that accurately measures CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer. These tests are optimized for easy use by collecting samples via an oral saline rinse and measured either via a point-of-care lateral flow assay or a laboratory kit. The test results, along with other clinical factors, can aid in the early diagnosis of oral cancer, potentially even before visual or physical indicators.
“We are pleased to announce this major milestone with the shipping of our OncAlert Oral Cancer product line to our global distributors,” said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant Biosciences. “Globally, we have seen a rise in oral and oropharyngeal cancer rates in recent years, and new tools to aid in the diagnosis of oral cancer earlier – such as the OncAlert Oral Cancer line – are critical to reducing the high death rate associated with this disease. We look forward to working with all of our distribution and commercialization partners to provide innovative and cost-effective products that will result in earlier detection and intervention for patients at risk all over the world.”
Vigilant Biosciences has previously announced multiple distribution agreements for its OncAlert Oral Cancer product line throughout Europe, Africa and Asia/Pacific and Latin America.
About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark™ Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.